SCM
AUPH icon

Silverarc Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Silverarc Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100,000
Closed -$2.29M – 70
2021
Q4 		$2.29M Buy
+100,000
New +$2.37M 0.93% 35

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Silverarc Capital Management's AUPH Position: Q1 2022 in Review

Silverarc Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2022, closing a stake of 100,000 shares — an estimated $2.29M sold.

Silverarc Capital Management first reported a position in AUPH in Q4 2021 and held it in 1 quarter. The position peaked at $2.29M in Q4 2021. 184 funds tracked by Wall St. Rank hold AUPH as of Q1 2022.

  • Silverarc Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Silverarc Capital Management sold 100,000 Aurinia Pharmaceuticals shares in Q1 2022, an estimated $2.29M.
  • Silverarc Capital Management first reported a position in Aurinia Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Silverarc Capital Management's Aurinia Pharmaceuticals position peaked at $2.29M in Q4 2021.
  • 184 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2022.

Based on Silverarc Capital Management's 13F filing for Q1 2022, filed 13 May 2022.